Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation
Metrics: PDF 1104 views | HTML 2268 views | ?
Sofia Nascimento dos Santos1, Helen Sheldon2, Jonathas Xavier Pereira3, Christopher Paluch4, Esther M Bridges2, Márcia Curry El-Cheikh5, Adrian L Harris2 and Emerson Soares Bernardes1
1Radiopharmacy Department, Nuclear Energy Research Institute, São Paulo, Brazil
2Department of Medical Oncology, Molecular Oncology Laboratories, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
3Department of Pathology, Faculty of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
4T-cell Biology Group, Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
5Institute for Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Emerson Soares Bernardes, email: email@example.com
Keywords: angiogenesis, cancer, galectin-3, Jagged-1, Notch
Received: March 09, 2016 Accepted: April 25, 2017 Published: May 09, 2017
Angiogenesis is a coordinated process tightly regulated by the balance between Delta-like-4 (DLL4) and Jagged-1 (JAG1) in endothelial cells. Here we show that galectin-3 (gal-3), a glycan-binding protein secreted by cancer cells under hypoxic conditions, triggers sprouting angiogenesis, assisted by hypoxic changes in the glycosylation status of endothelial cells that enhance binding to gal-3. Galectin-3’s proangiogenic functions were found to be predominantly dependent on the Notch ligand JAG1. Differential direct binding to JAG1 was shown by surface plasmon resonance assay. Upon binding to Notch ligands, gal-3 preferentially increased JAG1 protein half-life over DLL4 and preferentially activated JAG1/Notch-1 signaling in endothelial cells. JAG1 overexpression in Lewis lung carcinoma cells accelerated tumor growth in vivo, but this effect was prevented in Lgals3−/− mice. Our findings establish gal-3 as a molecular regulator of the JAG1/Notch-1 signaling pathway and have direct implications for the development of strategies aimed at controlling tumor angiogenesis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.